paclitaxel,CTX-009
Compass Therapeutics
[]
compass therapeutics announces that the phase 2 data of ctx-009 in combination with paclitaxel in patients with biliary tract cancers (btc) will be presented at the asco gi cancers symposium on january 20, 2023 $cmpx 
Real-Time News, Market Data, and Stock Quotes @ https://t.co/95MgYAZY8v - Sign Up For The Free Daily Biotech Pharma Investor Newsletter: https://t.co/79fkleaXz6